News
News
C-Path and Ventana Medical Systems to Collaborate on Developing Standardized Evaluation for Companion Diagnostic Tests and Targeted Cancer Therapies
C-Path has received a $2.1 million grant from Science Foundation Arizona to fund a collaboration project with the US FDA and the National Cancer Institute.
News
Enigma Diagnostics Announces a European Commission Award of EUR3 Million
The award will fund the development of a point of care platform for the rapid diagnosis of influenza infections.
News
GE and Lilly Collaborates to Co-Develop Molecular In-Vitro Diagnostics for Cancer Treatments
The collaboration is focused on developing diagnostic tools to predict patients’ response to targeted therapies.
News
New Nordic EMBL Partnership for Molecular Medicine
EMBL has partnered with Universities of Finland, Oslo and Umea to explore molecularly and genetically based treatments.
News
Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
The goal of collaboration is to create a breast cancer patient profile test to improve diagnosis and treatment for individualized medicine.
News
Agendia Joins the Personalized Medicine Coalition
The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling.
News
DxS K-RAS Mutation Detection Kit Used To Assess Tumour Mutation Status Prior to Treatment with Amgen’s Vectibix™
Amgen has selected Kit to analyse patient samples from the pivotal“408” study examining Vectibix versus best supportive care in patients with metastatic colorectal cancer.
News
Molecular Sensing to Commercialize New Biosensor Technology Exclusively Licensed from Vanderbilt University
MSI plans to produce biosensor products for research, diagnostic, biodefense and pharmacogenomic applications.
News
Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment
Software to save years in research that aligns patients and treatments.
News
Oxford Genome Sciences Announces New Therapeutic Antibody Deal with Medarex
New agreement to drive the development of OGeS’ own pipeline of antibodies in cancer.
Advertisement
